Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 256-276

  Lundquist, P ^a   Artursson, P ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bioavailability; Human intestinal tissue; Human Protein Atla; Nanoparticles; Oral drug delivery; Peptide drugs; Peptide permeability; Transcytosis; Transepithelial transport; Ussing chamber

Indexed keywords

BIOCHEMISTRY; CELL CULTURE; DRUG PRODUCTS; HISTOLOGY; NANOPARTICLES; PEPTIDES; PHYSIOLOGY; PROTEINS;

BIOAVAILABILITY; HUMAN PROTEINS; ORAL DRUG DELIVERY; PEPTIDE DRUGS; TRANSCYTOSIS; TRANSEPITHELIAL TRANSPORT; USSING CHAMBER;

TISSUE;

CELL PENETRATING PEPTIDE; INSULIN; NANOPARTICLE; PENETRATIN; PEPTIDE DERIVATIVE; POLYGLACTIN; PEPTIDE;

ANALYTICAL EQUIPMENT; CACO 2 CELL LINE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; INTESTINE SUBEPITHELIAL TISSUE; JEJUNUM; MOLECULAR INTERACTION; MUCUS SECRETION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS; USSING CHAMBER; ANIMAL; CYTOLOGY; INTESTINE; METABOLISM; PERMEABILITY;

ANIMALS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; NANOPARTICLES; PEPTIDES; PERMEABILITY;

EID: 84994082981     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.07.007     Document Type: Review

References (269)

1. [1] Date, A.A., Hanes, J., Ensign, L.M., Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J. Control. Release, 2016.
2. [2] Sinnecker, H., Krause, T., Koelling, S., Lautenschläger, I., Frey, A., The gut wall provides an effective barrier against nanoparticle uptake. Beilstein J. Nanotechnol. 5 (2014), 2092–2101.
3. [3] Hu, X., Fan, W., Yu, Z., Lu, Y., Qi, J., Zhang, J., Dong, X., Zhao, W., Wu, W., Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale 8 (2016), 7024–7035.
4. [4] Tsomaia, N., Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem. 94 (2015), 459–470.
5. [5] Doak, B.C., Over, B., Giordanetto, F., Kihlberg, J., Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21 (2014), 1115–1142.
6. [6] Palm, K., Stenberg, P., Luthman, K., Artursson, P., Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997), 568–571.
7. [7] Physiology of the Gastrointestinal Tract. 2006, Raven Press.
8. [8] Kiela, P.R., Ghishan, F.K., Physiology of intestinal absorption and secretion. Best Pract. Res. Clin. Gastroenterol. 30 (2016), 145–159.
9. [9] Goodman, B.E., Insights into digestion and absorption of major nutrients in humans. Adv. Physiol. Educ. 34 (2010), 44–53.
10. [10] Binder, H.J., Reuben, A., Nutrient digestion and absorption. Boron, W.F., Boulpaep, E.L., (eds.) Medical Physiology, 2012, Elsevier, Philadelphi, PA, USA, 949–979.
11. [11] Whitcomb, D.C., Lowe, M.E., Human pancreatic digestive enzymes. Dig. Dis. Sci. 52 (2007), 1–17.
12. [12] Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., Tissue-based map of the human proteome. Science, 347, 2015, 1260419.
13. [13] Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Towards a knowledge-based human protein atlas. Nat. Biotechnol. 28 (2010), 1248–1250.
14. [14] Ölander, M., Wiśniewski, J.R., Matsson, P., Lundquist, P., Artursson, P., The proteome of filter-grown Caco-2 cells with a focus on proteins involved in drug disposition. J. Pharm. Sci., 2016.
15. [15] Hubatsch, I., Lazorova, L., Vahlne, A., Artursson, P., Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium. Antimicrob. Agents Chemother. 49 (2005), 1087–1092.
16. [16] Bak, A., Gudmundsson, O.S., Friis, G.J., Siahaan, T.J., Borchardt, R.T., Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm. Res. 16 (1999), 24–29.
17. [17] Ungell, A.L., Andreasson, A., Lundin, K., Utter, L., Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J. Pharm. Sci. 81 (1992), 640–645.
18. [18] Koziolek, M., Grimm, M., Schneider, F., Jedamzik, P., Sager, M., Kühn, J.-P., Siegmund, W., Weitschies, W., Navigating the human gastrointestinal tract for oral drug delivery: uncharted waters and new frontiers. Adv. Drug Deliv. Rev. 101 (2016), 75–88.
19. [19] Davis, S., Hardy, J., Fara, J., Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986), 886–892.
20. [20] Lin, H.C., Prather, C., Fisher, R.S., Meyer, J.H., Summers, R.W., Pimentel, M., Mccallum, R.W., Akkermans, L.M., Loening-Baucke, V., A.T.F.C.o.G. Transit, Measurement of gastrointestinal transit. Dig. Dis. Sci. 50 (2005), 989–1004.
21. [21] Kararli, T.T., Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16 (1995), 351–380.
22. [22] Takashima, T., Shingaki, T., Katayama, Y., Hayashinaka, E., Wada, Y., Kataoka, M., Ozaki, D., Doi, H., Suzuki, M., Ishida, S., Dynamic analysis of fluid distribution in the gastrointestinal tract in rats: positron emission tomography imaging after oral administration of nonabsorbable marker, [18F] deoxyfluoropoly (ethylene glycol). Mol. Pharm. 10 (2013), 2261–2269.
23. [23] Lennernäs, H., Regårdh, C.-G., Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. Pharm. Res. 10 (1993), 130–135.
24. [24] Picard, C., Wysocki, J., Fioramonti, J., Griffiths, N., Intestinal and colonic motor alterations associated with irradiation-induced diarrhoea in rats. Neurogastroenterol. Motil. 13 (2001), 19–26.
25. [25] Aguirre, T., Teijeiro-Osorio, D., Rosa, M., Coulter, I., Alonso, M., Brayden, D., Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106 (2016), 223–241.
26. [26] Aguirre, T.A., Rosa, M., Coulter, I.S., Brayden, D.J., In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin. Eur. J. Pharm. Sci. 79 (2015), 102–111.
27. [27] Toth, I., Malkinson, J.P., Flinn, N.S., Drouillat, B., Horvath, A., Erchegyi, J., Idei, M., Venetianer, A., Artursson, P., Lazorova, L., Szende, B., Keri, G., Novel lipoamino acid- and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. J. Med. Chem. 42 (1999), 4010–4013.
28. [28] Pelaseyed, T., Bergström, J.H., Gustafsson, J.K., Ermund, A., Birchenough, G.M., Schütte, A., Post, S., Svensson, F., Rodríguez-Piñeiro, A.M., Nyström, E.E., The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 260 (2014), 8–20.
29. [29] Johansson, M.E., Ambort, D., Pelaseyed, T., Schütte, A., Gustafsson, J.K., Ermund, A., Subramani, D.B., Holmén-Larsson, J.M., Thomsson, K.A., Bergström, J.H., Composition and functional role of the mucus layers in the intestine. Cell. Mol. Life Sci. 68 (2011), 3635–3641.
30. [30] Corfield, A.P., Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim. Biophys. Acta Gen. Subj. 1850 (2015), 236–252.
31. [31] Jonckheere, N., Skrypek, N., Frénois, F., Van Seuningen, I., Membrane-bound mucin modular domains: from structure to function. Biochimie 95 (2013), 1077–1086.
32. [32] Wiśniewski, J.R., Ostasiewicz, P., Duś, K., Zielińska, D.F., Gnad, F., Mann, M., Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma. Mol. Syst. Biol., 8, 2012.
33. [33] Johansson, M.E., Hansson, G.C., Mucus and the goblet cell. Dig. Dis. 31 (2013), 305–309.
34. [34] Ambort, D., Johansson, M.E., Gustafsson, J.K., Nilsson, H.E., Ermund, A., Johansson, B.R., Koeck, P.J., Hebert, H., Hansson, G.C., Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin. Proc. Natl. Acad. Sci. 109 (2012), 5645–5650.
35. [35] van der Waaij, L.A., Harmsen, H.J., Madjipour, M., Kroese, F.G., Zwiers, M., Van Dullemen, H., De Boer, N., Welling, G., Jansen, P.L., Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm. Bowel Dis. 11 (2005), 865–871.
36. [36] Lai, S.K., Wang, Y.-Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61 (2009), 158–171.
37. [37] Atuma, C., Strugala, V., Allen, A., Holm, L., The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001), G922–G929.
38. [38] Hansson, G.C., Johansson, M.E., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Gut Microbes 1 (2010), 51–54.
39. [39] Bajka, B.H., Rigby, N.M., Cross, K.L., Macierzanka, A., Mackie, A.R., The influence of small intestinal mucus structure on particle transport ex vivo. Colloids Surf. B: Biointerfaces 135 (2015), 73–80.
40. [40] Hong, Z., Chasan, B., Bansil, R., Turner, B.S., Bhaskar, K.R., Afdhal, N.H., Atomic force microscopy reveals aggregation of gastric mucin at low pH. Biomacromolecules 6 (2005), 3458–3466.
41. [41] Gum, J.R., Byrd, J., Hicks, J.W., Toribara, N., Lamport, D., Kim, Y., Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism. J. Biol. Chem. 264 (1989), 6480–6487.
42. [42] Rong, M., Rossi, E.A., Zhang, J., McNeer, R.R., van den Brande, J.M., Yasin, M., Weed, D.T., Carothers Carraway, C.A., Thompson, J.F., Carraway, K.L., Expression and localization of Muc4/sialomucin complex (SMC) in the adult and developing rat intestine: implications for Muc4/SMC function. J. Cell. Physiol. 202 (2005), 275–284.
43. [43] Neutra, M.R., Mantis, N.J., Frey, A., Giannasca, P.J., The composition and function of M cell apical membranes: implications for microbial pathogenesis. Semin. Immunol. 11 (1999), 171–181.
44. [44] Frey, A., Giannasca, K.T., Weltzin, R., Giannasca, P.J., Reggio, H., Lencer, W.I., Neutra, M.R., Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 184 (1996), 1045–1059.
45. [45] Chantret, I., Barbat, A., Dussaulx, E., Brattain, M.G., Zweibaum, A., Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 48 (1988), 1936–1942.
46. [46] Phillips, T.E., Huet, C., Bilbo, P.R., Podolsky, D.K., Louvard, D., Neutra, M.R., Human intestinal goblet cells in monolayer culture: characterization of a mucus-secreting subclone derived from the HT29 colon adenocarcinoma cell line. Gastroenterology 94 (1988), 1390–1403.
47. [47] Birchenough, G., Johansson, M.E., Gustafsson, J., Bergström, J., Hansson, G., New developments in goblet cell mucus secretion and function. Mucosal Immunol. 8 (2015), 712–719.
48. [48] Vieira, M.A., Gomes, T.A., Ferreira, A.J., Knöbl, T., Servin, A.L., Liévin-Le Moal, V., Two atypical enteropathogenic Escherichia coli strains induce the production of secreted and membrane-bound mucins to benefit their own growth at the apical surface of human mucin-secreting intestinal HT29-MTX cells. Infect. Immun. 78 (2010), 927–938.
49. [49] Griffiths, P.C., Cattoz, B., Ibrahim, M.S., Anuonye, J.C., Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering. Eur. J. Pharm. Biopharm. 97 (2015), 218–222.
50. [50] Lieleg, O., Vladescu, I., Ribbeck, K., Characterization of particle translocation through mucin hydrogels. Biophys. J. 98 (2010), 1782–1789.
51. [51] Fordtran, J.S., Locklear, T.W., Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am. J. Dig. Dis. 11 (1966), 503–521.
52. [52] Yildiz, H.M., Speciner, L., Ozdemir, C., Cohen, D.E., Carrier, R.L., Food-associated stimuli enhance barrier properties of gastrointestinal mucus. Biomaterials 54 (2015), 1–8.
53. [53] Datta, S.S., Steinberg, A.P., Ismagilov, R.F., Polymers in the gut compress the colonic mucus hydrogel. Proc. Natl. Acad. Sci., 2016, 201602789.
54. [54] Olmsted, S.S., Padgett, J.L., Yudin, A.I., Whaley, K.J., Moench, T.R., Cone, R.A., Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81 (2001), 1930–1937.
55. [55] Lai, S.K., Wang, Y.-Y., Hida, K., Cone, R., Hanes, J., Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. 107 (2010), 598–603.
56. [56] Xu, Q., Ensign, L.M., Boylan, N.J., Schön, A., Gong, X., Yang, J.-C., Lamb, N.W., Cai, S., Yu, T., Freire, E., Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 9 (2015), 9217–9227.
57. [57] Ensign, L.M., Tang, B.C., Wang, Y.-Y., Terence, A.T., Hoen, T., Cone, R., Hanes, J., Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med., 4, 2012, 138ra179.
58. [58] Swavola, J.C., Edwards, T.D., Bevan, M.A., Direct measurement of macromolecule-coated colloid–mucus interactions. Langmuir 31 (2015), 9076–9085.
59. [59] Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., Huang, Y., Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9 (2015), 2345–2356.
60. [60] Artursson, P., Knight, S.D., Breaking the intestinal barrier to deliver drugs. Science 347 (2015), 716–717.
61. [61] Turner, J.R., Buschmann, M.M., Romero-Calvo, I., Sailer, A., Shen, L., The role of molecular remodeling in differential regulation of tight junction permeability. Semin. Cell Dev. Biol. 36 (2014), 204–212.
62. [62] Barmeyer, C., Schulzke, J.D., Fromm, M., Claudin-related intestinal diseases. Semin. Cell Dev. Biol. 42 (2015), 30–38.
63. [63] Günzel, D., Alan, S., Claudins and the modulation of tight junction permeability. Physiol. Rev. 93 (2013), 525–569.
64. [64] Mrsny, R.J., Brown, G.T., Gerner-Smidt, K., Buret, A.G., Meddings, J.B., Quan, C., Koval, M., Nusrat, A., A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am. J. Pathol. 172 (2008), 905–915.
65. [65] Suzuki, H., Nishizawa, T., Tani, K., Yamazaki, Y., Tamura, A., Ishitani, R., Dohmae, N., Tsukita, S., Nureki, O., Fujiyoshi, Y., Crystal structure of a claudin provides insight into the architecture of tight junctions. Science 344 (2014), 304–307.
66. [66] Taverner, A., Dondi, R., Almansour, K., Laurent, F., Owens, S.-E., Eggleston, I.M., Fotaki, N., Mrsny, R.J., Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J. Control. Release 210 (2015), 189–197.
67. [67] Eto, M., Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors. J. Biol. Chem. 284 (2009), 35273–35277.
68. [68] Lameris, A.L., Huybers, S., Kaukinen, K., Mäkelä, T.H., Bindels, R.J., Hoenderop, J.G., Nevalainen, P.I., Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease. Scand. J. Gastroenterol. 48 (2013), 58–69.
69. + deficiency and glucose malabsorption in mouse small intestine. Gastroenterology 140 (2011), 913–923.
70. [70] Noda, S., Tanabe, S., Suzuki, T., Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells. Mol. Nutr. Food Res. 57 (2013), 2019–2028.
71. [71] Weber, C.R., Raleigh, D.R., Su, L., Shen, L., Sullivan, E.A., Wang, Y., Turner, J.R., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285 (2010), 12037–12046.
72. [72] Clayburgh, D.R., Barrett, T.A., Tang, Y., Meddings, J.B., Van Eldik, L.J., Watterson, D.M., Clarke, L.L., Mrsny, R.J., Turner, J.R., Epithelial myosin light chain kinase–dependent barrier dysfunction mediates T cell activation–induced diarrhea in vivo. J. Clin. Invest. 115 (2005), 2702–2715.
73. [73] Zolotarevsky, Y., Hecht, G., Koutsouris, A., Gonzalez, D.E., Quan, C., Tom, J., Mrsny, R.J., Turner, J.R., A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123 (2002), 163–172.
74. [74] Wang, F., Graham, W.V., Wang, Y., Witkowski, E.D., Schwarz, B.T., Turner, J.R., Interferon-gamma; and Tumor Necrosis Factor-alpha; Synergize to Induce Intestinal Epithelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase Expression. Am. J. Pathol. 166 (2005), 409–419.
75. [75] Clayburgh, D.R., Musch, M.W., Leitges, M., Fu, Y.-X., Turner, J.R., Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J. Clin. Invest. 116 (2006), 2682–2694.
76. [76] Casselbrant, A., Elias, E., Fändriks, L., Wallenius, V., Expression of tight-junction proteins in human proximal small intestinal mucosa before and after Roux-en-Y gastric bypass surgery. Surg. Obes. Relat. Dis. 11 (2015), 45–53.
77. [77] Zeissig, S., Bürgel, N., Günzel, D., Richter, J., Mankertz, J., Wahnschaffe, U., Kroesen, A.J., Zeitz, M., Fromm, M., Schulzke, J.D., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56 (2007), 61–72.
78. [78] Bürgel, N., Bojarski, C., Mankertz, J., Zeitz, M., Fromm, M., Schulzke, J.D., Mechanisms of diarrhea in collagenous colitis. Gastroenterology 123 (2002), 433–443.
79. [79] Campbell, M., Hanrahan, F., Gobbo, O.L., Kelly, M.E., Kiang, A.-S., Humphries, M.M., Nguyen, A.T., Ozaki, E., Keaney, J., Blau, C.W., Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. Nat. Commun., 3, 2012, 849.
80. [80] Lindmark, T., Nikkilä, T., Artursson, P., Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 275 (1995), 958–964.
81. [81] Maher, S., Kennelly, R., Bzik, V.A., Baird, A.W., Wang, X., Winter, D., Brayden, D.J., Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. Eur. J. Pharm. Sci. 38 (2009), 291–300.
82. [82] Lindmark, T., Söderholm, J.D., Olaison, G., Alván, G., Ocklind, G., Artursson, P., Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm. Res. 14 (1997), 930–935.
83. [83] Terrak, M., Kerff, F., Langsetmo, K., Tao, T., Dominguez, R., Structural basis of protein phosphatase 1 regulation. Nature 429 (2004), 780–784.
84. +-glucose cotransport. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001), G1487–G1493.
85. [85] Feighery, L.M., Cochrane, S.W., Quinn, T., Baird, A.W., O'Toole, D., Owens, S.-E., O'Donoghue, D., Mrsny, R.J., Brayden, D.J., Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro. Pharm. Res. 25 (2008), 1377–1386.
86. [86] Kemper, A.C., Specian, R.D., Rat small intestinal mucins: a quantitative analysis. Anat. Rec. 229 (1991), 219–226.
87. [87] Grant, T.D., Specian, R.D., Proliferation of goblet cells and vacuolated cells in the rabbit distal colon. Anat. Rec. 252 (1998), 41–48.
88. [88] Mace, O., Tehan, B., Marshall, F., Pharmacology and physiology of gastrointestinal enteroendocrine cells. Pharmacol. Res. Perspect., 3, 2015.
89. [89] Karam, S.M., Lineage commitment and maturation of epithelial cells in the gut. Front. Biosci. 4 (1999), D286–D298.
90. [90] Mowat, A.M., Agace, W.W., Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 14 (2014), 667–685.
91. [91] Söderholm, J., The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol. Motil. 22 (2010), 718–733.
92. [92] Owen, R.L., Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 72 (1977), 440–451.
93. [93] Neutra, M.R., Frey, A., Kraehenbuhl, J.-P., Epithelial M cells: gateways for mucosal infection and immunization. Cell 86 (1996), 345–348.
94. [94] Ermund, A., Gustafsson, J.K., Hansson, G.C., Keita, Å.V., Mucus properties and goblet cell quantification in mouse, rat and human ileal Peyer's patches. PLoS One, 8, 2013, e83688.
95. [95] Niess, J.H., Reinecker, H.C., Dendritic cells in the recognition of intestinal microbiota. Cell. Microbiol. 8 (2006), 558–564.
96. [96] Helander, H.F., Fändriks, L., Surface area of the digestive tract—revisited. Scand. J. Gastroenterol. 49 (2014), 681–689.
97. [97] Miner-Williams, W.M., Stevens, B.R., Moughan, P.J., Are intact peptides absorbed from the healthy gut in the adult human?. Nutr. Res. Rev. 27 (2014), 308–329.
98. [98] Smith, D.E., Clémençon, B., Hediger, M.A., Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol. Asp. Med. 34 (2013), 323–336.
99. [99] Vives, E., Brodin, P., Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997), 16010–16017.
100. [100] Kauffman, W.B., Fuselier, T., He, J., Wimley, W.C., Mechanism matters: a taxonomy of cell penetrating peptides. Trends Biochem. Sci. 40 (2015), 749–764.
101. [101] Dupont, E., Prochiantz, A., Joliot, A., Penetratin story: an overview. Cell-Penetrating Pept. Methods Protoc., 2015, 29–37.
102. [102] Marks, J.R., Placone, J., Hristova, K., Wimley, W.C., Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. J. Am. Chem. Soc. 133 (2011), 8995–9004.
103. [103] Kristensen, M., Nielsen, H.M., Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals. Basic Clin. Pharmacol. Toxicol. 118 (2016), 99–106.
104. [104] Zhu, S., Chen, S., Gao, Y., Guo, F., Li, F., Xie, B., Zhou, J., Zhong, H., Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv., 2015, 1–12.
105. [105] Dupont, E., Prochiantz, A., Joliot, A., Identification of a signal peptide for unconventional secretion. J. Biol. Chem. 282 (2007), 8994–9000.
106. [106] Preston, J.E., Abbott, N.J., Begley, D.J., Chapter five-transcytosis of macromolecules at the blood–brain barrier. Adv. Pharmacol. 71 (2014), 147–163.
107. [107] Doherty, G.J., McMahon, H.T., Mechanisms of endocytosis. Annu. Rev. Biochem. 78 (2009), 857–902.
108. [108] Sockolosky, J.T., Tiffany, M.R., Szoka, F.C., Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc. Natl. Acad. Sci. 109 (2012), 16095–16100.
109. [109] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C., Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
110. [110] Rojas, R., Apodaca, G., Immunoglobulin transport across polarized epithelial cells. Nat. Rev. Mol. Cell Biol. 3 (2002), 944–956.
111. [111] Wolf, J.S., Li, G., Varadhachary, A., Petrak, K., Schneyer, M., Li, D., Ongkasuwan, J., Zhang, X., Taylor, R.J., Strome, S.E., Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin. Cancer Res. 13 (2007), 1601–1610.
112. [112] Mahidhara, G., Kanwar, R.K., Roy, K., Kanwar, J.R., Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. Int. J. Nanomedicine, 10, 2015, 4081.
113. [113] Fazen, C.H., Valentin, D., Fairchild, T.J., Doyle, R.P., Oral delivery of the appetite suppressing peptide hPYY (3–36) through the vitamin B12 uptake pathway. J. Med. Chem. 54 (2011), 8707–8711.
114. [114] Alpers, D.H., Russell-Jones, G., Gastric intrinsic factor: the gastric and small intestinal stages of cobalamin absorption. A personal journey. Biochimie 95 (2013), 989–994.
115. [115] Verma, A., Sharma, S., Gupta, P.K., Singh, A., Teja, B.V., Dwivedi, P., Gupta, G.K., Trivedi, R., Mishra, P.R., Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: a mucoadhesive and pH responsive carrier for improved oral delivery of insulin. Acta Biomater., 2015.
116. [116] Chalasani, K.B., Russell-Jones, G.J., Jain, A.K., Diwan, P.V., Jain, S.K., Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122 (2007), 141–150.
117. [117] Cohen, M., Kitsberg, D., Tsytkin, S., Shulman, M., Aroeti, B., Nahmias, Y., Live imaging of GLUT2 glucose-dependent trafficking and its inhibition in polarized epithelial cysts. Open Biol., 4, 2014, 140091.
118. [118] Guan, C., Ji, J., Jin, C., Wang, G., Li, X., Guan, W., Expression of cholera toxin B subunit – lumbrokinase in edible sunflower seeds – the use of transmucosal carrier to enhance its fusion protein's effect on protection of rats and mice against thrombosis. Biotechnol. Prog. 30 (2014), 1029–1039.
119. [119] Kohli, N., Westerveld, D.R., Ayache, A.C., Verma, A., Shil, P., Prasad, T., Zhu, P., Chan, S.L., Li, Q., Daniell, H., Oral delivery of bioencapsulated proteins across blood–brain and blood–retinal barriers. Mol. Ther. 22 (2014), 535–546.
120. [120] Noakes, K.L., Teisserenc, H.T., Lord, J.M., Dunbar, P., Cerundolo, V., Roberts, L.M., Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett. 453 (1999), 95–99.
121. [121] Ryou, J.-H., Sohn, Y.-K., Hwang, D.-E., Kim, H.-S., Shiga-like toxin-based high-efficiency and receptor-specific intracellular delivery system for a protein. Biochem. Biophys. Res. Commun. 464 (2015), 1282–1289.
122. [122] Hurley, B.P., Jacewicz, M., Thorpe, C., Lincicome, L.L., King, A.J., Keusch, G.T., Acheson, D.W., Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect. Immun. 67 (1999), 6670–6677.
123. [123] te Welscher, Y.M., Chinnapen, D.J.-F., Kaoutzani, L., Mrsny, R.J., Lencer, W.I., Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1. J. Control. Release 175 (2014), 72–78.
124. [124] Battogtokh, G., Ko, Y.T., Self-assembled chitosan-ceramide nanoparticle for enhanced oral delivery of paclitaxel. Pharm. Res. 31 (2014), 3019–3030.
125. [125] Wang, N., Wang, T., Zhang, M., Chen, R., Niu, R., Deng, Y., Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system. Eur. J. Pharm. Biopharm. 88 (2014), 194–206.
126. [126] Situ, W., Li, X., Liu, J., Chen, L., Preparation and characterization of glycoprotein-resistant starch complex as a coating material for oral bioadhesive microparticles for colon-targeted polypeptide delivery. J. Agric. Food Chem. 63 (2015), 4138–4147.
127. [127] Mayor, S., Parton, R.G., Donaldson, J.G., Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol., 6, 2014, a016758.
128. [128] Ritter, B., Murphy, S., Dokainish, H., Girard, M., Gudheti, M.V., Kozlov, G., Halin, M., Philie, J., Jorgensen, E.M., Gehring, K., NECAP 1 regulates AP-2 interactions to control vesicle size, number, and cargo during clathrin-mediated endocytosis. PLoS Biol., 11, 2013, e1001670.
129. [129] Miller, S.E., Mathiasen, S., Bright, N.A., Pierre, F., Kelly, B.T., Kladt, N., Schauss, A., Merrifield, C.J., Stamou, D., Höning, S., CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature. Dev. Cell 33 (2015), 163–175.
130. [130] Pelkmans, L., Helenius, A., Endocytosis via caveolae. Traffic 3 (2002), 311–320.
131. [131] Falcone, S., Cocucci, E., Podini, P., Kirchhausen, T., Clementi, E., Meldolesi, J., Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J. Cell Sci. 119 (2006), 4758–4769.
132. [132] Corda, D., Carcedo, C.H., Bonazzi, M., Luini, A., Spano, S., Molecular aspects of membrane fission in the secretory pathway. Cell. Mol. Life Sci. 59 (2002), 1819–1832.
133. [133] Praefcke, G.J., McMahon, H.T., The dynamin superfamily: universal membrane tubulation and fission molecules?. Nat. Rev. Mol. Cell Biol. 5 (2004), 133–147.
134. [134] Rieux, A. des, Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Préat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65 (2013), 833–844.
135. [135] Zhang, X., Wu, W., Ligand-mediated active targeting for enhanced oral absorption. Drug Discov. Today 19 (2014), 898–904.
136. [136] Fowler, R., Vllasaliu, D., Trillo, F.F., Garnett, M., Alexander, C., Horsley, H., Smith, B., Whitcombe, I., Eaton, M., Stolnik, S., Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 9 (2013), 3282–3294.
137. [137] Rieux, A. des, Ragnarsson, E.G., Gullberg, E., Préat, V., Schneider, Y.-J., Artursson, P., Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25 (2005), 455–465.
138. [138] Gullberg, E., Leonard, M., Karlsson, J., Hopkins, A.M., Brayden, D., Baird, A.W., Artursson, P., Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279 (2000), 808–813.
139. [139] Kirchhausen, T., Macia, E., Pelish, H.E., Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol. 438 (2008), 77–93.
140. [140] Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., Kirchhausen, T., Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10 (2006), 839–850.
141. [141] Ivanov, A.I., Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?. Exocytosis Endocytosis, 2008, 15–33.
142. [142] Vercauteren, D., Vandenbroucke, R.E., Jones, A.T., Rejman, J., Demeester, J., De Smedt, S.C., Sanders, N.N., Braeckmans, K., The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol. Ther. 18 (2010), 561–569.
143. [143] Stenmark, H., Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10 (2009), 513–525.
144. [144] Hutagalung, A.H., Novick, P.J., Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev. 91 (2011), 119–149.
145. [145] Rodriguez-Boulan, E., Macara, I.G., Organization and execution of the epithelial polarity programme. Nat. Rev. Mol. Cell Biol. 15 (2014), 225–242.
146. [146] Hunziker, W., Peters, P.J., Rab17 localizes to recycling endosomes and regulates receptor-mediated transcytosis in epithelial cells. J. Biol. Chem. 273 (1998), 15734–15741.
147. [147] Casanova, J.E., Wang, X., Kumar, R., Bhartur, S.G., Navarre, J., Woodrum, J.E., Altschuler, Y., Ray, G.S., Goldenring, J.R., Association of Rab25 and Rab11a with the apical recycling system of polarized Madin-Darby canine kidney cells. Mol. Biol. Cell 10 (1999), 47–61.
148. [148] Sheff, D.R., Daro, E.A., Hull, M., Mellman, I., The receptor recycling pathway contains two distinct populations of early endosomes with different sorting functions. J. Cell Biol. 145 (1999), 123–139.
149. [149] Sandin, P., Fitzpatrick, L.W., Simpson, J.C., Dawson, K.A., High-speed imaging of Rab family small GTPases reveals rare events in nanoparticle trafficking in living cells. ACS Nano 6 (2012), 1513–1521.
150. [150] Ullrich, O., Reinsch, S., Urbé, S., Zerial, M., Parton, R.G., Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol. 135 (1996), 913–924.
151. [151] Taub, M.E., Shen, W.C., Polarity in the transcytotic processing of apical and basal membrane-bound peroxidase-polylysine conjugates in MDCK cells. J. Cell. Physiol. 150 (1992), 283–290.
152. [152] He, W., Ladinsky, M.S., Huey-Tubman, K.E., Jensen, G.J., McIntosh, J.R., Björkman, P.J., FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455 (2008), 542–546.
153. [153] Taub, M.E., Shen, W.-C., Regulation of pathways within cultured epithelial cells for the transcytosis of a basal membrane-bound peroxidase-polylysine conjugate. J. Cell Sci. 106 (1993), 1313–1322.
154. [154] Prydz, K., Hansen, S.H., Sandvig, K., van Deurs, B., Effects of brefeldin A on endocytosis, transcytosis and transport to the Golgi complex in polarized MDCK cells. J. Cell Biol. 119 (1992), 259–272.
155. [155] Cammisotto, P.G., Bendayan, M., Sané, A., Dominguez, M., Garofalo, C., Levy, E., Receptor-mediated transcytosis of leptin through human intestinal cells in vitro. Int. J. Cell Biol., 2010, 2010.
156. [156] S.J., Mansour, S.J., Zhao, X.H., Giordano, J., Scherer, S.W., Melançon, P., p200 ARF-GEP1: a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is targeted by the drug brefeldin A. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 7968–7973.
157. [157] Donaldson, J.G., Finazzi, D., Klausner, R.D., Brefeldin A Inhibits Golgi Membrane-catalysed Exchange of Guanine Nucleotide onto ARF Protein. 1992.
158. [158] Cluett, E.B., Wood, S.A., Banta, M., Brown, W.J., Tubulation of Golgi membranes in vivo and in vitro in the absence of brefeldin A. J. Cell Biol. 120 (1993), 15–24.
159. [159] Takashima, K., Saitoh, A., Hirose, S., Nakai, W., Kondo, Y., Takasu, Y., Kakeya, H., Shin, H.-W., Nakayama, K., GBF1-Arf-COPI-ArfGAP-mediated Golgi-to-ER transport involved in regulation of lipid homeostasis. Cell Struct. Funct. 36 (2011), 223–235.
160. [160] Strous, G., Van Kerkhof, P., Van Meer, G., Rijnboutt, S., Stoorvogel, W., Differential effects of brefeldin A on transport of secretory and lysosomal proteins. J. Biol. Chem. 268 (1993), 2341–2347.
161. [161] Scheel, J., Pepperkok, R., Lowe, M., Griffiths, G., Kreis, T.E., Dissociation of coatomer from membranes is required for brefeldin A-induced transfer of Golgi enzymes to the endoplasmic reticulum. J. Cell Biol. 137 (1997), 319–333.
162. [162] Guidi, R., Levi, L., Rouf, S.F., Puiac, S., Rhen, M., Frisan, T., Salmonella enterica delivers its genotoxin through outer membrane vesicles secreted from infected cells. Cell. Microbiol. 15 (2013), 2034–2050.
163. [163] El Baya, A., Linnemann, R., von Olleschik-Elbheim, L., Robenek, H., Schmidt, M., Endocytosis and retrograde transport of pertussis toxin to the Golgi complex as a prerequisite for cellular intoxication. Eur. J. Cell Biol. 73 (1997), 40–48.
164. [164] Chinnapen, D.J.-F., Chinnapen, H., Saslowsky, D., Lencer, W.I., Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol. Lett. 266 (2007), 129–137.
165. [165] Nakai, W., Kondo, Y., Saitoh, A., Naito, T., Nakayama, K., Shin, H.-W., ARF1 and ARF4 regulate recycling endosomal morphology and retrograde transport from endosomes to the Golgi apparatus. Mol. Biol. Cell 24 (2013), 2570–2581.
166. [166] Su, T., Bryant, D.M., Luton, F., Vergés, M., Ulrich, S.M., Hansen, K.C., Datta, A., Eastburn, D.J., Burlingame, A.L., Shokat, K.M., A kinase cascade leading to Rab11-FIP5 controls transcytosis of the polymeric immunoglobulin receptor. Nat. Cell Biol. 12 (2010), 1143–1153.
167. [167] Baker, K., Qiao, S.-W., Kuo, T., Kobayashi, K., Yoshida, M., Lencer, W.I., Blumberg, R.S., Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin. Immunopathol. 31 (2009), 223–236.
168. [168] Tzaban, S., Massol, R.H., Yen, E., Hamman, W., Frank, S.R., Lapierre, L.A., Hansen, S.H., Goldenring, J.R., Blumberg, R.S., Lencer, W.I., The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J. Cell Biol. 185 (2009), 673–684.
169. [169] Dickinson, B.L., Badizadegan, K., Wu, Z., Ahouse, J.C., Zhu, X., Simister, N.E., Blumberg, R.S., Lencer, W.I., Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest. 104 (1999), 903–911.
170. [170] Wu, Z., Simister, N.E., Tryptophan- and dileucine-based endocytosis signals in the neonatal Fc receptor. J. Biol. Chem. 276 (2001), 5240–5247.
171. [171] Pabst, O., Mowat, A., Oral tolerance to food protein. Mucosal Immunol. 5 (2012), 232–239.
172. [172] Rath, T., Kuo, T.T., Baker, K., Qiao, S.-W., Kobayashi, K., Yoshida, M., Roopenian, D., Fiebiger, E., Lencer, W.I., Blumberg, R.S., The immunologic functions of the neonatal Fc receptor for IgG. J. Clin. Immunol. 33 (2013), 9–17.
173. [173] Bitonti, A.J., Dumont, J.A., Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58 (2006), 1106–1118.
174. [174] Dumont, J.A., Bitonti, A.J., Clark, D., Evans, S., Pickford, M., Newman, S.P., Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 18 (2005), 294–303.
175. [175] Vllasaliu, D., Alexander, C., Garnett, M., Eaton, M., Stolnik, S., Fc-mediated transport of nanoparticles across airway epithelial cell layers. J. Control. Release 158 (2012), 479–486.
176. [176] Fyfe, J.C., Madsen, M., Højrup, P., Christensen, E.I., Tanner, S.M., de la Chapelle, A., He, Q., Moestrup, S.K., The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood 103 (2004), 1573–1579.
177. [177] Pedersen, G.A., Chakraborty, S., Steinhauser, A.L., Traub, L.M., Madsen, M., AMN directs endocytosis of the intrinsic factor-vitamin B12 receptor cubam by engaging ARH or Dab2. Traffic 11 (2010), 706–720.
178. [178] Alpers, D.H., Absorption and blood/cellular transport of folate and cobalamin: pharmacokinetic and physiological considerations. Biochimie, 2015.
179. [179] Allen, L.H., How common is vitamin B-12 deficiency?. Am. J. Clin. Nutr. 89 (2009), 693S–696S.
180. [180] He, H., Wang, P., Cai, C., Yang, R., Tang, X., VB 12-coated Gel-Core-SLN containing insulin: another way to improve oral absorption. Int. J. Pharm. 493 (2015), 451–459.
181. [181] Wrackmeyer, U., Hansen, G.H., Seya, T., Danielsen, E.M., Intelectin: a novel lipid raft-associated protein in the enterocyte brush border. Biochemistry 45 (2006), 9188–9197.
182. [182] Lönnerdal, B., Jiang, R., Du, X., Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. J. Pediatr. Gastroenterol. Nutr. 53 (2011), 606–614.
183. [183] Jiang, R., Lopez, V., Kelleher, S.L., Lönnerdal, B., Apo-and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in caco-2 cells. J. Cell. Physiol. 226 (2011), 3022–3031.
184. [184] Prades, R., Oller-Salvia, B., Schwarzmaier, S.M., Selva, J., Moros, M., Balbi, M., Grazú, V., de La Fuente, J.M., Egea, G., Plesnila, N., Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood–brain barrier. Angew. Chem. Int. Ed. 54 (2015), 3967–3972.
185. [185] Gulec, S., Anderson, G.J., Collins, J.F., Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 307 (2014), G397–G409.
186. [186] Griffiths, W.J., Cox, T.M., Co-localization of the mammalian hemochromatosis gene product (HFE) and a newly identified transferrin receptor (TfR2) in intestinal tissue and cells. J. Histochem. Cytochem. 51 (2003), 613–623.
187. [187] Zheng, W., Kollmeyer, J., Symolon, H., Momin, A., Munter, E., Wang, E., Kelly, S., Allegood, J.C., Liu, Y., Peng, Q., Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta Biomembr. 1758 (2006), 1864–1884.
188. [188] Zeidan, Y.H., Hannun, Y.A., Translational aspects of sphingolipid metabolism. Trends Mol. Med. 13 (2007), 327–336.
189. [189] Hanada, K., Kumagai, K., Yasuda, S., Miura, Y., Kawano, M., Fukasawa, M., Nishijima, M., Molecular machinery for non-vesicular trafficking of ceramide. Nature 426 (2003), 803–809.
190. [190] Chinnapen, D.J.-F., Hsieh, W.-T., te Welscher, Y.M., Saslowsky, D.E., Kaoutzani, L., Brandsma, E., D'Auria, L., Park, H., Wagner, J.S., Drake, K.R., Lipid sorting by ceramide structure from plasma membrane to ER for the cholera toxin receptor ganglioside GM1. Dev. Cell 23 (2012), 573–586.
191. [191] Saslowsky, D.E., te Welscher, Y.M., Chinnapen, D.J.-F., Wagner, J.S., Wan, J., Kern, E., Lencer, W.I., Ganglioside GM1-mediated transcytosis of cholera toxin bypasses the retrograde pathway and depends on the structure of the ceramide domain. J. Biol. Chem. 288 (2013), 25804–25809.
192. [192] Powell, J.J., Thomas-McKay, E., Thoree, V., Robertson, J., Hewitt, R.E., Skepper, J.N., Brown, A., Hernandez-Garrido, J.C., Midgley, P.A., Gomez-Morilla, I., An endogenous nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune cells. Nat. Nanotechnol., 2015.
193. [193] Söderholm, J.D., Gut immunology: nanoparticles ferry gut antigens. Nat. Nanotechnol. 10 (2015), 298–299.
194. [194] Neutra, M.R., Mantis, N.J., Kraehenbuhl, J.-P., Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol. 2 (2001), 1004–1009.
195. [195] Wallon, C., Braaf, Y., Wolving, M., Olaison, G., Söderholm, J.D., Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand. J. Gastroenterol. 40 (2005), 586–595.
196. [196] Foltz, M., Cerstiaens, A., van Meensel, A., Mols, R., van der Pijl, P.C., Duchateau, G.S., Augustijns, P., The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. Peptides 29 (2008), 1312–1320.
197. [197] Van Kruiningen, H.J., West, A.B., Freda, B.J., Holmes, K.A., Distribution of Peyer's patches in the distal ileum. Inflamm. Bowel Dis. 8 (2002), 180–185.
198. [198] Van Kruiningen, H., Ganley, L., Freda, B., The role of Peyer's patches in the age-related incidence of Crohn's disease. J. Clin. Gastroenterol. 25 (1997), 470–475.
199. [199] Tyrer, P.C., Foxwell, A.R., Kyd, J.M., Otczyk, D.C., Cripps, A.W., Receptor mediated targeting of M-cells. Vaccine 25 (2007), 3204–3209.
200. [200] Kraehenbuhl, J.-P., Neutra, M.R., Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16 (2000), 301–332.
201. [201] Gullberg, E., Keita, Å.V., Sa'ad, Y.S., Andersson, M., Caldwell, K.D., Söderholm, J.D., Artursson, P., Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J. Pharmacol. Exp. Ther. 319 (2006), 632–639.
202. [202] Soni, J., Baird, A.W., O'Brien, L.M., McElroy, M., Callanan, J.J., Bassett, H.F., Campion, D., Brayden, D.J., Rat, ovine and bovine Peyer's patches mounted in horizontal diffusion chambers display sampling function. J. Control. Release 115 (2006), 68–77.
203. [203] Parayath, N.N., Nehoff, H., Mueller, P., Taurin, S., Greish, K., Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery—dual uptake through enterocytes and M-cells. Int. J. Nanomedicine, 10, 2015, 4653.
204. [204] Damgé, C., Aprahamian, M., Humbert, W., Pinget, M., Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol. 52 (2000), 1049–1056.
205. [205] Pappo, J., Ermak, T., Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. Clin. Exp. Immunol., 76, 1989, 144.
206. [206] De Jesus, M., Ostroff, G.R., Levitz, S.M., Bartling, T.R., Mantis, N.J., A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling β-glucan microparticles. PLoS One, 9, 2014, e91002.
207. [207] Shreedhar, V.K., Kelsall, B.L., Neutra, M.R., Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches. Infect. Immun. 71 (2003), 504–509.
208. [208] Lawless, E., Griffin, B.T., O'Mahony, A., O'Driscoll, C.M., Exploring the impact of drug properties on the extent of intestinal lymphatic transport—in vitro and in vivo studies. Pharm. Res. 32 (2015), 1817–1829.
209. [209] YOSHIKAWA, H., TAKADA, K., MURANISHI, S., Molecular weight dependence of permselectivity to rat small intestinal blood-lymph barrier for exogenous macromolecules absorbed from lumen. J. Pharmacobio-Dyn. 7 (1984), 1–6.
210. [210] Rothenfluh, D.A., Bermudez, H., O'Neil, C.P., Hubbell, J.A., Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat. Mater. 7 (2008), 248–254.
211. [211] Patil, P.B., Chougule, P.B., Kumar, V.K., Almström, S., Bäckdahl, H., Banerjee, D., Herlenius, G., Olausson, M., Sumitran-Holgersson, S., Recellularization of acellular human small intestine using bone marrow stem cells. Stem Cells Transl. Med., 2013, 10.5966/sctm.2012-0108.
212. [212] Barnes, C.A., Brison, J., Michel, R., Brown, B.N., Castner, D.G., Badylak, S.F., Ratner, B.D., The surface molecular functionality of decellularized extracellular matrices. Biomaterials 32 (2011), 137–143.
213. [213] Artursson, P., Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J. Pharm. Sci. 79 (1990), 476–482.
214. [214] Wilson, G., Hassan, I.F., Dix, C.J., Williamson, I., Shah, R., Mackay, M., Artursson, P., Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Control. Release 11 (1990), 25–40.
215. [215] Hilgers, A.R., Conradi, R.A., Burton, P.S., Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7 (1990), 902–910.
216. [216] Hidalgo, I.J., Raub, T.J., Borchardt, R.T., Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96 (1989), 736–749.
217. [217] Hubatsch, I., Ragnarsson, E.G., Artursson, P., Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2 (2007), 2111–2119.
218. [218] Tavelin, S., Gråsjö, J., Taipalensuu, J., Ocklind, G., Artursson, P., Applications of epithelial cell culture in studies of drug transport. Epithelial Cell Cult. Protoc., 2002, 233–272.
219. [219] Wikman, A., Karlsson, J., Carlstedt, I., Artursson, P., A drug absorption model based on the mucus layer producing human intestinal goblet cell line HT29-H. Pharm. Res. 10 (1993), 843–852.
220. [220] Karlsson, J., Wikman, A., Artursson, P., The mucus layer as a barrier to drug absorption in monolayers of human intestinal epithelial HT29-H goblet cells. Int. J. Pharm. 99 (1993), 209–218.
221. [221] Hilgendorf, C., Spahn-Langguth, H., Regårdh, C.G., Lipka, E., Amidon, G.L., Langguth, P., Caco-2 versus caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. J. Pharm. Sci. 89 (2000), 63–75.
222. [222] Wikman-Larhed, A., Artursson, P., Co-cultures of human intestinal goblet (HT29-H) and absorptive (Caco-2) cells for studies of drug and peptide absorption. Eur. J. Pharm. Sci. 3 (1995), 171–183.
223. [223] Schimpel, C., Teubl, B., Absenger, M., Meindl, C., Fröhlich, E., Leitinger, G., Zimmer, A., Roblegg, E., Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles. Mol. Pharm. 11 (2014), 808–818.
224. [224] Behrens, I., Stenberg, P., Artursson, P., Kissel, T., Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm. Res. 18 (2001), 1138–1145.
225. [225] Keely, S., Rullay, A., Wilson, C., Carmichael, A., Carrington, S., Corfield, A., Haddleton, D.M., Brayden, D.J., In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm. Res. 22 (2005), 38–49.
226. [226] Grießinger, J., Dünnhaupt, S., Cattoz, B., Griffiths, P., Oh, S., Gómez, S.B.i., Wilcox, M., Pearson, J., Gumbleton, M., Abdulkarim, M., Methods to determine the interactions of micro-and nanoparticles with mucus. Eur. J. Pharm. Biopharm. 96 (2015), 464–476.
227. [227] Quest, A.F., Gutierrez-Pajares, J.L., Torres, V.A., Caveolin-1: an ambiguous partner in cell signalling and cancer. J. Cell. Mol. Med. 12 (2008), 1130–1150.
228. [228] Hehlgans, S., Cordes, N., Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance. Am. J. Cancer Res. 1 (2011), 521–530.
229. [229] Dasgupta, N., Thakur, B.K., Ta, A., Das, S., Caveolin-1 is transcribed from a hypermethylated promoter to mediate colonocyte differentiation and apoptosis. Exp. Cell Res. 334 (2015), 323–336.
230. [230] Ilina, P., Partti, S., Niklander, J., Ruponen, M., Lou, Y.-R., Yliperttula, M., Effect of differentiation on endocytic profiles of endothelial and epithelial cell culture models. Exp. Cell Res. 332 (2015), 89–101.
231. [231] Kernéis, S., Bogdanova, A., Kraehenbuhl, J.-P., Pringault, E., Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 277 (1997), 949–952.
232. [232] Miyake, M., Ragnarsson, E., Nakai, D., Artursson, P., The pro-inflammatory cytokine interleukin-6 regulates nanoparticle transport across model follicle-associated epithelium cells. J. Pharm. Sci., 2016.
233. [233] Ragnarsson, E.G., Schoultz, I., Gullberg, E., Carlsson, A.H., Tafazoli, F., Lerm, M., Magnusson, K.-E., Söderholm, J.D., Artursson, P., Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab. Investig. 88 (2008), 1215–1226.
234. [234] Dharmsathaphorn, K., Carlson, S., Structural analysis of a human intestinal epithelial cell line. Gastroenterology 92 (1987), 1133–1145.
235. [235] Tavelin, S., Milovic, V., Ocklind, G., Olsson, S., Artursson, P., A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J. Pharmacol. Exp. Ther. 290 (1999), 1212–1221.
236. [236] Paul, E., Hochman, J., Quaroni, A., Conditionally immortalized intestinal epithelial cells: novel approach for study of differentiated enterocytes. Am. J. Phys. Cell Phys. 265 (1993), C266–C278.
237. [237] Takenaka, T., Harada, N., Kuze, J., Chiba, M., Iwao, T., Matsunaga, T., Human small intestinal epithelial cells differentiated from adult intestinal stem cells as a novel system for predicting oral drug absorption in humans. Drug Metab. Dispos. 42 (2014), 1947–1954.
238. [238] Takenaka, T., Harada, N., Kuze, J., Chiba, M., Iwao, T., Matsunaga, T., Application of a human intestinal epithelial cell monolayer to the prediction of oral drug absorption in humans as a superior alternative to the caco-2 cell monolayer. J. Pharm. Sci. 105 (2016), 915–924.
239. [239] Navabi, N., McGuckin, M.A., Lindén, S.K., Gastrointestinal cell lines form polarized epithelia with an adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. PLoS One, 8, 2013, e68761.
240. [240] Kim, S.H., Chi, M., Yi, B., Kim, S.H., Oh, S., Kim, Y., Park, S., Sung, J.H., Three-dimensional intestinal villi epithelium enhances protection of human intestinal cells from bacterial infection by inducing mucin expression. Integr. Biol. 6 (2014), 1122–1131.
241. [241] Bhatia, S.N., Ingber, D.E., Microfluidic organs-on-chips. Nature, 201, 2014, 4.
242. [242] Kim, H.J., Ingber, D.E., Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. 5 (2013), 1130–1140.
243. [243] Kim, H.J., Huh, D., Hamilton, G., Ingber, D.E., Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12 (2012), 2165–2174.
244. [244] Persson, P.B., Ussing's chamber origin. Acta Physiol., 2016.
245. [245] Kalman, S.M., Ussing, H.H., Active sodium uptake by the toad and its response to the antidiuretic hormone. J. Gen. Physiol. 38 (1955), 361–370.
246. [246] Schmidt, C., Lautenschlaeger, C., Collnot, E.-M., Schumann, M., Bojarski, C., Schulzke, J.-D., Lehr, C.-M., Stallmach, A., Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa—a first in vivo study in human patients. J. Control. Release 165 (2013), 139–145.
247. [247] Lautenschläger, C., Schmidt, C., Lehr, C.-M., Fischer, D., Stallmach, A., PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 85 (2013), 578–586.
248. [248] Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E.C., Biryukov, S., Abbafati, C., Abera, S.F., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
249. [249] Teixeira, T.F., Collado, M.C., Ferreira, C.L., Bressan, J., Peluzio, Mdo C., Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr. Res. 32 (2012), 637–647.
250. [250] Ding, S., Lund, P.K., Role of intestinal inflammation as an early event in obesity and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care, 14, 2011, 328.
251. [251] Raybould, H.E., Gut microbiota, epithelial function and derangements in obesity. J. Physiol. 590 (2012), 441–446.
252. [252] Lau, E., Marques, C., Pestana, D., Santoalha, M., Carvalho, D., Freitas, P., Calhau, C., The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutr. Metab., 13, 2016, 1.
253. [253] Kless, C., Müller, V.M., Schüppel, V.L., Lichtenegger, M., Rychlik, M., Daniel, H., Klingenspor, M., Haller, D., Diet-induced obesity causes metabolic impairment independent of alterations in gut barrier integrity. Mol. Nutr. Food Res. 59 (2015), 968–978.
254. [254] Farhadi, A., Gundlapalli, S., Shaikh, M., Frantzides, C., Harrell, L., Kwasny, M.M., Keshavarzian, A., Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28 (2008), 1026–1033.
255. [255] Sjöberg, Å., Lutz, M., Tannergren, C., Wingolf, C., Borde, A., Ungell, A.-L., Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. Eur. J. Pharm. Sci. 48 (2013), 166–180.
256. [256] Gitter, A.H., Fromm, M., Schulzke, J.-D., Impedance analysis for the determination of epithelial and subepithelial resistance in intestinal tissues. J. Biochem. Biophys. Methods 37 (1998), 35–46.
257. [257] Clarke, L.L., A guide to Ussing chamber studies of mouse intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009), G1151–G1166.
258. [258] Reis, J., Dezani, A., Pereira, T., Avdeef, A., Serra, C., Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum. Eur. J. Pharm. Sci. 48 (2013), 781–789.
259. [259] McNamara, B., Winter, D.C., Cuffe, J.E., O'Sullivan, G.C., Harvey, B.J., Basolateral K + channel involvement in forskolin-activated chloride secretion in human colon. J. Physiol. 519 (1999), 251–260.
260. [260] Schipper, N.G., Vårum, K.M., Stenberg, P., Ocklind, G., Lennernäs, H., Artursson, P., Chitosans as absorption enhancers of poorly absorbable drugs: 3: influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8 (1999), 335–343.
261. [261] Rawlinson, L.-A.B., O'Brien, P.J., Brayden, D.J., High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. J. Control. Release 146 (2010), 84–92.
262. [262] Brayden, D.J., Cryan, S.-A., Dawson, K.A., O'Brien, P.J., Simpson, J.C., High-content analysis for drug delivery and nanoparticle applications. Drug Discov. Today 20 (2015), 942–957.
263. [263] van de Kerkhof, E.G., Ungell, A.-L.B., Sjöberg, Å.K., de Jager, M.H., Hilgendorf, C., de Graaf, I.A., Groothuis, G.M., Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations. Drug Metab. Dispos. 34 (2006), 1893–1902.
264. [264] Rozehnal, V., Nakai, D., Hoepner, U., Fischer, T., Kamiyama, E., Takahashi, M., Yasuda, S., Mueller, J., Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur. J. Pharm. Sci. 46 (2012), 367–373.
265. [265] Hornby, P.J., Cooper, P.R., Kliwinski, C., Ragwan, E., Mabus, J.R., Harman, B., Thompson, S., Kauffman, A.L., Yan, Z., Tam, S.H., Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm. Res. 31 (2014), 908–922.
266. [266] Calleja, P., Espuelas, S., Vauthier, C., Ponchel, G., Irache, J.M., Controlled release, intestinal transport, and oral bioavailablity of paclitaxel can be considerably increased using suitably tailored pegylated poly (anhydride) nanoparticles. J. Pharm. Sci. 104 (2015), 2877–2886.
267. [267] Chen, J., Liu, C., Shan, W., Xiao, Z., Guo, H., Huang, Y., Enhanced stability of oral insulin in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin. J. Microencapsul. 32 (2015), 632–641.
268. [268] Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88 (2014), 518–528.
269. [269] Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., Paalzow, L.K., Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9 (1992), 1243–1251.